Home » Stocks » ETON

Eton Pharmaceuticals, Inc. (ETON)

Stock Price: $7.97 USD 0.14 (1.79%)
Updated Apr 23, 2021 11:00 AM EDT - Market open
Market Cap 189.74M
Revenue (ttm) 39,000
Net Income (ttm) -27.97M
Shares Out 24.48M
EPS (ttm) -1.33
PE Ratio n/a
Forward PE 36.76
Dividend n/a
Dividend Yield n/a
Trading Day April 23
Last Price $7.97
Previous Close $7.83
Change ($) 0.14
Change (%) 1.79%
Day's Open 7.90
Day's Range 7.83 - 8.06
Day's Volume 21,146
52-Week Range 4.21 - 10.30

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Eton Pharmaceuticals, Inc. (ETON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the n...

1 week ago - Zacks Investment Research

DEER PARK, Ill., March 17, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases,...

1 month ago - GlobeNewsWire

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -23.08% and -92.21%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the...

1 month ago - Zacks Investment Research

DEER PARK, Ill., March 16, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases,...

1 month ago - GlobeNewsWire

Eton Pharmaceuticals, Inc. (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

DEER PARK, Ill., March 04, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare ...

1 month ago - GlobeNewsWire

DEER PARK, Ill., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare ...

2 months ago - GlobeNewsWire

Eton Pharmaceuticals Inc (NASDAQ: ETON) has sold its neurology portfolio that includes lamotrigine (ET-105), zonisamide (ET-104), and topiramate (ET-101) product candidates, to Azurity Pharmaceuticals. ...

2 months ago - Benzinga

DEER PARK, Ill., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare ...

2 months ago - GlobeNewsWire

DEER PARK, Ill., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare ...

3 months ago - GlobeNewsWire

Application Assigned a PDUFA Date of August 6, 2021 Application Assigned a PDUFA Date of August 6, 2021

4 months ago - GlobeNewsWire

DEER PARK, Ill., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare p...

4 months ago - GlobeNewsWire

Eton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

DEER PARK, Ill., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare p...

6 months ago - GlobeNewsWire

- Application Assigned a PDUFA Date of May 29, 2021 - Application Assigned a PDUFA Date of May 29, 2021

6 months ago - GlobeNewsWire

DEER PARK, Ill., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare p...

6 months ago - GlobeNewsWire

DEER PARK, Ill. , Oct. 13, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare ...

6 months ago - GlobeNewsWire

Eton Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

6 months ago - Zacks Investment Research

- Application Submitted for the Treatment of Partial-Onset Seizures and Migraine

6 months ago - GlobeNewsWire

-ALKINDI SPRINKLE is the first and only FDA-approved granular hydrocortisone formulation for adrenocortical insufficiency specifically designed for children

6 months ago - GlobeNewsWire

After an initial rejection in 2019 and a string of delays following a refiling of the regulatory application, Eton Pharmaceuticals Inc's ETON 1.47% out-licensed allergic conjunctivitis ophthalmic soluti...

Other stocks mentioned: BHC
6 months ago - Benzinga

LAVAL, QC and DEER PARK, Ill., Sept. 25, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), Bausch + Lomb, a leading global eye health business, and Eton Pharmaceutical...

6 months ago - PRNewsWire

DEER PARK, Ill., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, rep...

7 months ago - GlobeNewsWire

DEER PARK, Ill., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, toda...

7 months ago - GlobeNewsWire

Eton Pharmaceuticals' (ETON) CEO Sean Brynjelsen on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of 17.86% and -93.85%, respectively, for the quarter ended June 2020.

8 months ago - Zacks Investment Research

Shares of Eton Pharmaceuticals (NASDAQ:ETON) fell 1.5% in pre-market trading after the company reported Q2 results.

8 months ago - Benzinga

DEER PARK, Ill., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, toda...

8 months ago - GlobeNewsWire

-Granted Orphan Drug Designation by the FDA for the Treatment of Methanol Poisoning

8 months ago - GlobeNewsWire

Eton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -108.33% and -93.89%, respectively, for the quarter ended March 2020.

11 months ago - Zacks Investment Research

DEER PARK, Ill., May 14, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today...

11 months ago - GlobeNewsWire

Eton Pharmaceuticals Inc (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

11 months ago - Zacks Investment Research

-Eton confirms first-to-file ANDA referencing Exela Pharma Sciences’ Elcys product

11 months ago - GlobeNewsWire

Eton Pharmaceuticals, Inc. (ETON) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

11 months ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor Eton Pharmaceuticals

1 year ago - Zacks Investment Research

-Estimated Market Opportunity of Greater than $100 Million

1 year ago - GlobeNewsWire

Eton Pharmaceuticals, Inc. (ETON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

1 year ago - Zacks Investment Research

-Results Demonstrated Bioequivalence to the Currently Approved Oral Solid Formulation

1 year ago - GlobeNewsWire

Eton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of 48.28% and -54.55%, respectively, for the quarter ended December 2019.

1 year ago - Zacks Investment Research

Eton Pharmaceuticals: Many Catalysts To Watch Out For In 2020

1 year ago - Seeking Alpha

DEER PARK, Ill., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, toda...

1 year ago - GlobeNewsWire

Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.

Other stocks mentioned: CLVS, IMMU, PRGO, VTVT
1 year ago - Zacks Investment Research

DEER PARK, Ill., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, ann...

1 year ago - GlobeNewsWire

A Small Bet On Eton Pharmaceuticals

1 year ago - Seeking Alpha

~  Biorphen is the First and Only Ready-to-Use FDA-Approved Injectable Formulation of  Phenylephrine ~

1 year ago - GlobeNewsWire

Eton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

DEER PARK, Ill., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, toda...

1 year ago - GlobeNewsWire

About ETON

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. It also devel... [Read more...]

Industry
Biotechnology
IPO Date
Nov 13, 2018
Stock Exchange
NASDAQ
Ticker Symbol
ETON
Full Company Profile

Financial Performance

In 2020, ETON's revenue was $39,000, a decrease of -95.93% compared to the previous year's $959,000. Losses were -$27.97 million, 52.7% more than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for ETON stock is "Buy." The 12-month stock price forecast is 13.50, which is an increase of 69.39% from the latest price.

Price Target
$13.50
(69.39% upside)
Analyst Consensus: Buy